Methylnaltrexone: Peripherally Acting µ-Opioid Receptor Antagonist

Area of Science:

• Gastroenterology
• Pharmacology
• Pain Management

Background:

• Opioid-induced constipation (OIC) is a prevalent and persistent adverse effect of opioid therapy.
• Conventional laxatives often fail to provide adequate relief for OIC.
• Refractory OIC necessitates alternative treatment strategies.

Purpose of the Study:

• To review the role of peripherally acting µ-opioid receptor antagonists (PAMORAs) in managing OIC.
• To highlight the specific indications and appropriate use of methylnaltrexone for OIC.
• To inform advanced practitioners on optimizing PAMORA therapy for OIC.

Main Methods:

• Literature review of PAMORAs and their efficacy in OIC treatment.
• Analysis of methylnaltrexone's approved indications for OIC.
• Discussion of clinical considerations for using PAMORAs in advanced illness and chronic noncancer pain.

Main Results:

• PAMORAs are effective for OIC unresponsive to traditional laxatives.
• Methylnaltrexone is indicated for OIC in adults with advanced illness and chronic noncancer pain.
• Understanding PAMORA mechanisms and indications is crucial for effective patient management.

Conclusions:

• PAMORAs represent a valuable therapeutic class for refractory OIC.
• Methylnaltrexone offers targeted relief for specific OIC patient groups.
• Clinicians should be knowledgeable about PAMORA use for improved OIC management.